Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

surveillance

  • Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018
    Susceptibility
    Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

    Ceftobiprole medocaril is an advanced-generation cephalosporin prodrug that has qualified infectious disease product status granted by the US FDA and is currently being evaluated in phase 3 clinical trials in patients with acute bacterial skin and skin structure infections (ABSSSIs) and in patients with Staphylococcus aureus bacteremia. In this study, the activity of...

    Robert K. Flamm, Leonard R. Duncan, Kamal A. Hamed, Jennifer I. Smart, Rodrigo E. Mendes, Michael A. Pfaller
  • Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018
    Epidemiology and Surveillance
    Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018

    Omadacycline is a broad-spectrum aminomethylcycline approved in October 2018 by the U.S. Food and Drug Administration for treating acute bacterial skin and skin structure infections and community-acquired pneumonia as both an oral and intravenous once-daily formulation. In this report, the activities of omadacycline and comparators were tested against 49,000 nonduplicate bacterial isolates collected prospectively during 2016 to 2018...

    Michael A. Pfaller, Michael D. Huband, Dee Shortridge, Robert K. Flamm
  • <em>In Vitro</em> Activity of Minocycline against U.S. Isolates of <span class="named-content genus-species" id="named-content-1">Acinetobacter baumannii-</span><span class="named-content genus-species" id="named-content-2">Acinetobacter calcoaceticus</span> Species Complex, <span class="named-content genus-species" id="named-content-3">Stenotrophomonas maltophilia</span>, and <span class="named-content genus-species" id="named-content-4">Burkholderia cepacia</span> Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018
    Epidemiology and Surveillance
    In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

    We evaluated the activity of minocycline and comparator agents against a large number of Stenotrophomonas maltophilia (n = 1,289), Acinetobacter baumannii-Acinetobacter calcoaceticus species complex (n = 1,081),...

    Robert K. Flamm, Dee Shortridge, Mariana Castanheira, Helio S. Sader, Michael A. Pfaller
  • Open Access
    Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates
    Editor's Pick Analytical Procedures
    Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates

    Antimicrobial resistance (AMR) is a major public health problem that requires publicly available tools for rapid analysis. To identify AMR genes in whole-genome sequences, the National Center for Biotechnology Information (NCBI) has produced AMRFinder, a tool that identifies AMR genes using a high-quality curated AMR gene reference database.

    Michael Feldgarden, Vyacheslav Brover, Daniel H. Haft, Arjun B. Prasad, Douglas J. Slotta, Igor Tolstoy, Gregory H. Tyson, Shaohua Zhao, Chih-Hao Hsu, Patrick F. McDermott, Daniel A. Tadesse, Cesar Morales, Mustafa Simmons, Glenn Tillman, Jamie Wasilenko, Jason P. Folster, William Klimke
  • Open Access
    Joint Modeling of Resistance to Six Antimicrobials in Urinary <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Isolates in Quebec, Canada
    Epidemiology and Surveillance
    Joint Modeling of Resistance to Six Antimicrobials in Urinary Escherichia coli Isolates in Quebec, Canada

    Empirical treatment of urinary tract infections should be based on susceptibility profiles specific to the locale and patient population. Additionally, these susceptibility profiles should account for correlations between resistance to different types of antimicrobials.

    Jean-Paul R. Soucy, Alexandra M. Schmidt, Charles Frenette, Patrick Dolcé, Alexandre A. Boudreault, David L. Buckeridge, Caroline Quach
  • Open Access
    The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program
    Epidemiology and Surveillance
    The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program

    Bloodstream infection (BSI) organisms were consecutively collected from >200 medical centers in 45 nations between 1997 and 2016. Species identification and susceptibility testing followed Clinical and Laboratory Standards Institute broth microdilution methods at a central laboratory.

    Daniel J. Diekema, Po-Ren Hsueh, Rodrigo E. Mendes, Michael A. Pfaller, Kenneth V. Rolston, Helio S. Sader, Ronald N. Jones
  • U.S.-Based National Surveillance for Fidaxomicin Susceptibility of <span class="named-content genus-species" id="named-content-1">Clostridioides difficile</span>-Associated Diarrheal Isolates from 2013 to 2016
    Susceptibility
    U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016

    In 2011, we initiated a sentinel surveillance network to assess changes in Clostridioides (formerly Clostridium) difficile antimicrobial susceptibility to fidaxomicin from 6 geographically dispersed medical centers in the United States. This report summarizes data from 2013 to 2016. C. difficile isolates or toxin-positive stools from...

    C. M. Thorpe, L. A. McDermott, M. K. Tran, J. Chang, S. G. Jenkins, E. J. C. Goldstein, R. Patel, B. A. Forbes, S. Johnson, D. N. Gerding, D. R. Snydman
  • <em>In Vitro</em> Activity of Ceftazidime-Avibactam against Clinical Isolates of <span class="named-content genus-species" id="named-content-1">Enterobacteriaceae</span> and <span class="named-content genus-species" id="named-content-2">Pseudomonas aeruginosa</span> Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
    Epidemiology and Surveillance
    In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

    The International Network for Optimal Resistance Monitoring (INFORM) global surveillance program collected clinical isolates of Enterobacteriaceae (n = 7,665) and Pseudomonas aeruginosa (n = 1,794) from 26 medical centers in six Latin American countries from 2012 to 2015. The ...

    James A. Karlowsky, Krystyna M. Kazmierczak, Samuel K. Bouchillon, Boudewijn L. M. de Jonge, Gregory G. Stone, Daniel F. Sahm
  • Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016
    Susceptibility
    Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

    Ceftobiprole is an advanced cephalosporin with potent activity against Gram-positive and Gram-negative bacteria that has been approved in many European and non-European countries to treat community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). This study reports on the activity of ceftobiprole against a large set of clinical isolates obtained from hospitalized patients in the United States in 2016 that...

    Michael A. Pfaller, Robert K. Flamm, Rodrigo E. Mendes, Jennifer M. Streit, Jennifer I. Smart, Kamal A. Hamed, Leonard R. Duncan, Helio S. Sader
  • <em>In Vitro</em> Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying <span class="named-content genus-species" id="named-content-1">Enterobacteriaceae</span> Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
    Epidemiology and Surveillance
    In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015

    Enterobacteriaceae producing the Ambler class D OXA-48 carbapenemase, combined with additional resistance mechanisms, such as permeability defects or cocarriage of class A, B, or C β-lactamases, can become highly resistant to most β-lactams currently in use, including carbapenems. A total of 45,872 ...

    Krystyna M. Kazmierczak, Patricia A. Bradford, Gregory G. Stone, Boudewijn L. M. de Jonge, Daniel F. Sahm

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596